May 16th 2023
A prospective study on patients with DR and CKD found no significant effect on renal function shortly after performing fluorescein angiography.
March 26th 2023
February 21st 2023
Making Sense of Hepatitis C Management in Chronic Kidney DiseaseFebruary 8th 2023
Kim Zuber, PA-C, and Jane Davis, DNP, provide perspective on guideline recommendations for the management of hepatitis C in people with chronic kidney disease from the Kidney Disease Improving Global Outcomes.
Daprodustat Receives FDA Approval for Anemia Caused by CKD on DialysisFebruary 1st 2023
Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.
Study Estimates Event-Free Survival with Combination SGLT2 and ACE/ARBs in People without DiabetesNovember 23rd 2022
Using data from a trio of trials, investigators provide insight into the potential benefits of combination therapy with SGLT2 inhibitors and RAAS inhibition on event-free survival among patients with chronic kidney disease without diabetes.
Key Takeaways from the ADA-KDIGO Consensus Statement on CKD, with Kim Zuber, MS, PA-C, and Jane Davis, DNPNovember 17th 2022
Kim Zuber, MS, PA-C, and Jane Davis, DNP, provide perspective on the recent consensus statement on management of chronic kidney disease from the American Diabetes Association and the Kidney Disease Improving Global Outcomes group.
Finerenone Reduces Negative CV Outcomes in Type 2 Diabetes, Irrespective of Baseline Kidney FunctionOctober 25th 2022
An analysis of data from the FIDELITY program suggests use of finerenone reduced negative heart failure outcomes in people with diabetes and chronic kidney disease, regardless of baseline kidney function.
Obesity Society, National Kidney Foundation Release Report on Managing Coexisting Obesity and Kidney DiseaseOctober 21st 2022
Released on October 21, the special joint report from the Obesity Society and National Kidney Foundation outlines the hurdles, optimization strategies, and research needs for the management of coexisiting obesity and chronic kidney disease identified during a multispecialty, scientific workshop held in April 2021.
Managing CKD in the Face of a Growing Diabetes Epidemic, with Amy Mottl, MDOctober 17th 2022
In an interview at the 6th annual Cardio-Endo-Renal Collaborative from Physicians' Education Resource, Amy Mottl, MD, provides perspective on recent data from the CURE-CKD registry and problems facing nephrologists as they cope with an increasing prevalence of diabetes.
Study Details "Troubling" Rates of Chronic Kidney Disease in People with DiabetesOctober 14th 2022
An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.
Risk of Kidney Decline in T1D Heightened for People of African Caribbean EthnicitySeptember 3rd 2022
An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.
Finerenone Reduces All-Cause Mortality, Sudden Cardiac Death in Type 2 DiabetesAugust 29th 2022
An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.
Real-World Data Links Rosuvastatin to NephrotoxicityJuly 22nd 2022
An analysis of real-world EHR data from more than 900,000 statin users suggests use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation compared to atorvastatin use.
Increased Physical Activity Linked to Lower Cardiovascular Risk in Chronic Kidney DiseaseJuly 13th 2022
An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.
Invasive Approach More Beneficial than Medical Management for NSTEMI in Chronic Kidney DiseaseJune 24th 2022
New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.
Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022June 6th 2022
After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.
Tirzepatide and Kidney Outcomes, with Hiddo Heerspink, PharmD, PhDJune 5th 2022
Hiddo Heerspink, PharmD, PhD, discusses a SURPASS-4 analysis examining kidney outcomes among patients receiving tirzepatide vs insulin glargine and provides perspective on the next steps for research as well as education.
Tirzepatide Use Can Slow Progression of CKD in Type 2 DiabetesJune 3rd 2022
An analysis of SURPASS-4 data presented at ADA 2022 details the apparent reduction in progression of chronic kidney disease observed with use of tirzepatide compared to insulin glargine in the phase 3 trial, with a 41% reduction in progression of CKD in T2D.